

**APPENDIX**

Below is an example of a potential weekly schedule (PA split: HSC=5, QUB=5) which should be regarded as flexible and averaged over the year (for example - the post holder could have the ability to clear the schedule of HSC work at times when needing to organise examinations in the annual student assessments). This example is illustrative for a candidate interested in haematological malignancy, but all other sub-speciality interests in haematology that fit with our PGJCCR research focus can be accommodated. The final job plan will be agreed between the successful candidate, the PGJCCR Director in QUB and the relevant Clinical Director (and/or Divisional Chair) in BHSCT.

**Illustrative Job Plan:**

Day	Time	Work Activity	Location	No. of PAs		
				DCC	QUB	SPA
Monday	09.00-14.00	QUB	QUB		1.25	
	14.00-17.00	QUB	QUB			0.75
Tuesday	09.00-13.00	Haematology clinic	BCH	1.0		
	13.00-17.00	QUB	QUB		1.0	
Wednesday	09.00-11.00	Teaching ward round	BCH	0.5		
	11.00-13.00	Clinical Administration	BCH	0.5		
	13.00-17.00	QUB	QUB		1.0	
Thursday	09.00-13.00	New and review Haematology patient clinic	BCH	1.0		
	13.00-16.00	Haematology MDM	BCH	0.75		
	16.00-17.00	Clinical Administration	BCH	0.25		
Friday	09.00-10.00	Grand Rounds	BCH			0.25
	10.00-12.00	Audit/Governance/M&M/QI	BCH			0.5
	12.00-13.00	Clinical Administration	BCH	0.25		
	13.00-17.00	QUB	QUB		1.0	
		<b>Hours: 40</b>		<b>10.0</b>	<b>4.25</b>	<b>4.25</b>
<b>Total</b>						

**Summary of 10 Programmed Activities (PAs):**

DPC 4.25

QPA 4.25

SPA 1.5 (0.75 QUB + 0.75 BHSCT)

Total = 10.00

## Emergency Work:

This section includes all, of your prospective emergency on-call work and the agreed availability for on-call.

Participation in the haematology consultant on-call rota and in provision of acute haematology are desirable however it is not mandatory and are negotiable with BHSCT.

On-call rota	To be agreed
Category	To be agreed
On-call supplement	To be agreed

## Background Information

### Patrick G Johnston Centre for Cancer Research (PGJCCR)

Research in the School of Medicine, Dentistry and Biomedical Sciences (SMDBS, Head of School Prof Pascal McKeown) is co-ordinated through our three leading discipline-based centres of excellence: the Centre for Public Health (CPH), Wellcome-Wolfson Institute for Experimental Medicine (WWIEM), and the Patrick G Johnston Centre for Cancer Research (PGJCCR). The Northern Ireland Clinical Research Facility (NICRF) is also part through the School. The School is committed to interdisciplinary research and each of these research centres work together providing cross-cutting disciplinary expertise in different disease areas of strength, particularly in clinical trials. This will be supported by the Institute of Research Excellence in Advanced Clinical Healthcare (iREACH), a new innovation project supported by the Belfast Region City Deal to drive enhanced collaboration of academia, industry and public sector to drive evaluation of drugs and integration into care pathways.

The PGJCCR, which was formed as a virtual Centre in 2004 under the leadership of Prof Patrick Johnston, moved in 2007 into a bespoke 5000m<sup>2</sup> purpose-built facility close to the regional Northern Ireland Cancer Centre (NICC), providing an academic-clinical interface for translational science. In 2015, the Centre expanded to occupy an additional 3000m<sup>2</sup> in the adjacent Health Sciences Building (HSB). Today, PGJCCR has 44 Principal Investigators (PIs), led by Prof Chris Scott.

In total the Centre has >120 staff, complemented by 75 post-graduate research (PGR) and 40 postgraduate taught (PGT) students. Industrial partnerships form a key element of the PGJCCR, acknowledging that successful impact in cancer research requires close multi-sectoral collaborations. The Centre also has a UK-leading Public and Patient Involvement (PPI) strategy, devised in collaboration with the Northern Ireland Cancer Research Consumer Forum. Within PGJCCR there are established translational scientists with active research programmes in the epigenetics, DNA repair or immune responses within blood cancers. In addition, there is established cohort of clinical academics in both surgical oncology and medical and clinical oncology.

There is full support for phase I – IV cancer clinical trials and translational studies through the Belfast Experimental Cancer Medicine Centre (Clinical Lead Dr Vicky Coyle and Scientific Lead Prof. Dan Longley) and the N. Ireland Cancer Trials Network (Clinical Director Mr Stuart McIntosh). Haematology has an active trials portfolio currently lead by Prof McMullin. It is a Trials Acceleration Programme (TAP) funded haematology centre and has a current cohort of 3 haematology research nurses and 3 data managers.

For further details of the clinical and translational research infrastructure in place, please see the websites below:

<https://www.qub.ac.uk/research-centres/cancer-research/>

<http://www.ecmcnetwork.org.uk/belfast>

<http://www.nictn.hscni.net>